JAK1 is a human tyrosine kinase protein essential for signaling for certain type I and type II cytokines.

JH1 is the kinase domain important for the enzymatic activity of the JAK and contains typical features of a tyrosine kinase such as conserved tyrosines necessary for JAK activation (e.g., Y1038/Y1039 in JAK1, Y1007/Y1008 in JAK2, Y980/Y981 in JAK3, and Y1054/Y1055 in Tyk2).

2024年12月25日 · This gene is a key component of the interleukin-6 (IL-6)/JAK1/STAT3 immune and inflammation response and is a therapeutic target for alleviating cytokine storms. The kinase activity of this gene is directly inhibited by the suppressor of …

2021年11月26日 · In liver fibrosis, JAK1 is a constitutive TGFβRI-binding protein; thus, STAT3 is activated directly through JAK1 within minutes of TGFβ stimulation in a SMAD-independent manner.

2024年8月21日 · In this review, we outline the structural basis that governs key nodes in this pathway, offering a comprehensive overview of the signal transduction process. Furthermore, we explore recent advances...

We used JAK-deficient cell-lines and structure-based mutagenesis to study the function of JAK1 and its pseudokinase domain (JH2) in cytokine signaling pathways that employ JAK1 with different JAK heterodimerization partner.

tyrosine-protein kinase JAK1. The Janus kinase 1 is critical for pancreatic cancer initiation and progression. Individuals with JAK1 variants are affected by syndromic features encompassing autoimmunity, atopy, colitis, and dermatitis.

2024年2月20日 · This gene is a key component of the interleukin-6 (IL-6)/JAK1/STAT3 immune and inflammation response and is a therapeutic target for alleviating cytokine storms. The kinase activity of this gene is directly inhibited by the suppressor of …

2022年8月24日 · One, called Janus kinase 1 (JAK1), is a member of a new class of PTKs characterized by the presence of a second phosphotransferase-related domain immediately N-terminal to the PTK domain--hence the name Janus.

The valine residue at amino acid 658 in JAK1 is functionally equivalent to V617 in JAK2 ; i.e., it is critically important for negative regulation of JAK kinase activity. To our knowledge, JAK1 mutations have never been described in MPNs or CMML, so this is the first case report.